Has Debra Powell, MD received payments from drug or device companies?

Yes. Drug and device makers reported $833 in general payments to Debra Powell, MD across 23 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Debra Powell, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Debra Powell, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Debra Powell, MD

Infectious Disease · West Reading, PANPI 1649483272

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.5% of the total across 23 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Paratek Pharmaceuticals, Inc. at 32.3% of the total. Reporting peaked in 2019 at $552 and has fallen 95.1% since, to $27 in 2025.

$833in general payments, 2019–2025

Across 23 payments — averaging $36.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Paratek Pharmaceuticals, Inc.$269
AbbVie$198
Merck$160
Gilead$83
Melinta Therapeutics, LLC$33
Genentech, Inc.$19
plus $71 from 4 others

$438,787in research payments, 2019–2025

Across 19 payments — averaging $23,094 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$341K
Arrow International, Inc.$79K
Mannkind Corporation$9K
Emergent Biosolutions Inc.$6K
Sanofi Pasteur Inc.$4K

What the payments were for

Food & beverage$77092%
Education$638%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Paratek Pharmaceuticals, Inc.	4	$269
AbbVie	4	$198
Merck	4	$160
Gilead	4	$83
Melinta Therapeutics, LLC	2	$33
Genentech, Inc.	1	$19
Insmed, Inc.	1	$18
Viiv Healthcare Company	1	$18
Alk-abello, Inc	1	$18
Tetraphase Pharmaceuticals, Inc.	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

NUZYRA$125
ZERBAXA$118

How this compares

$833 in reported general payments places this provider in the 75th percentile of 457 infectious disease providers in Pennsylvania.

See all infectious disease providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$26,086

Medicare patients

178

Services billed

260

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala	84	$325,851
TriumeqAbacavir/Dolutegravir/Lamivudi	31	$118,982
OdefseyEmtricitab/Rilpiviri/Tenof Ala	15	$52,188
TivicayDolutegravir Sodium	14	$30,267
PifeltroDoravirine	11	$18,269
Cefepime Hcl	12	$3,574
ShingrixVaricella-Zoster Ge/As01b/Pf	16	$3,298
Vancomycin Hcl	13	$2,170
Boostrix TdapDiphth,pertuss(Acell),tet Vac	17	$959
Cefadroxil	23	$499
Azithromycin	11	$359
Cephalexin	17	$43
Sodium Chloride0.9 % Sodium Chloride	14	$15

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
GileadBiktarvy	$83	$325,85184 claims
Viiv Healthcare CompanyTriumeq, Tivicay	$18	$149,24845 claims
MerckPifeltro	$160	$18,26911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 457 infectious disease providers in Pennsylvania.